Targeting TDP-43 in neurodegenerative diseases

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 6, 2014, Pages 617-632

  Budini, Mauricio ^a   Baralle, Francisco E ^a   Buratti, Emanuele ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

Amyotrophic lateral sclerosis; Frontotemporal dementia; HnRNP; Protein aggregation; RNA metabolism; TAR DNA binding protein 43

Indexed keywords

TAR DNA BINDING PROTEIN; DNA BINDING PROTEIN; PROTEIN TDP-43; RNA;

AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; FRONTOTEMPORAL DEMENTIA; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; PROTEIN TARGETING; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; HUMAN; METABOLISM; NEURODEGENERATIVE DISEASES; PHYSIOLOGY; PROTEIN AGGREGATION, PATHOLOGICAL;

ANIMALS; DNA-BINDING PROTEINS; HUMANS; NEURODEGENERATIVE DISEASES; PROTEIN AGGREGATION, PATHOLOGICAL; RNA;

EID: 84900810303     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.896905     Document Type: Review

References (124)

1. Castello A, Fischer B, Hentze MW, Preiss T. RNA-binding proteins in mendelian disease. Trends Genet 2013;29(5):318-27
2. Romano M, Buratti E. Targeting RNA binding proteins involved in neurodegeneration. J Biomol Screen 2013;18(9):967-83
3. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314(5796):130-3
4. Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006;351(3):602-11
5. Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008;319(5870):1668-72
6. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009;323(5918):1205-8
7. Vance C, Rogelj B, Hortobagyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009;323(5918):1208-11
8. Mackenzie IR, Neumann M. FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis. Brain Res 2012;1462:40-3
9. Kim HJ, Kim NC, Wang YD, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 2013;495(7442):467-73
10. Cruts M, Gijselinck I, Van Langenhove T, et al. Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends Neurosci 2013;36(8):450-9
11. Lee YB, Chen HJ, Peres JN, et al. Hexanucleotide repeats in ALS/FTD form length-dependent RNA Foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep 2013;5(5):1178-86
12. Janssens J, Van Broeckhoven C. Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders. Hum Mol Genet 2013;22(R1):R77-87
13. Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 2013;79(3):416-38
14. Buratti E, Baralle FE. TDP-43: gumming up neurons through proteinprotein and protein-RNA interactions. Trends Biochem Sci 2012;37(6):237-47
15. Dreyfuss G, Kim VN, Kataoka N. Messenger-RNA-binding proteins and the messages they carry. Nat Rev Mol Cell Biol 2002;3(3):195-205
16. Norris AD, Calarco JA. Emerging roles of alternative pre-mRNA splicing regulation in neuronal development and function. Front Neurosci 2012;6:122
17. Tsao W, Jeong YH, Lin S, et al. Rodent models of TDP-43: recent advances. Brain Res 2012;1462:26-39
18. Buratti E, Romano M, Baralle FE. TDP-43 high throughput screening analyses in neurodegeneration: advantages and pitfalls. Mol Cell Neurosci 2013;56C(465):74
19. Donnelly CJ, Zhang PW, Pham JT, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 2013;80(2):415-28
20. Douglas PM, Dillin A. Protein homeostasis and aging in neurodegeneration. J Cell Biol 2010;190(5):719-29
21. Sephton CF, Cenik C, Kucukural A, et al. Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. J Biol Chem 2011;286(2):1204-15
22. Ayala YM, Zago P, D'Ambrogio A, et al. Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci 2008;121(Pt 22):3778-85
23. Swanson MS, Dreyfuss G. Classification and purification of proteins of heterogeneous nuclear ribonucleoprotein particles by RNA-binding specificities. Mol Cell Biol 1988;8(5):2237-41
24. Pinol-Roma S, Choi YD, Matunis MJ, et al. Immunopurification of heterogeneous nuclear ribonucleoprotein particles reveals an assortment of RNA-binding proteins. Genes Dev 1988;2(2):215-27
25. Ling SC, Albuquerque CP, Han JS, et al. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc Natl Acad Sci USA 2010;107(30):13318-23
26. Freibaum BD, Chitta RK, High AA, et al. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J Proteome Res 2010;9(2):1104-20
27. Morelli X, Bourgeas R, Roche P. Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I). Curr Opin Chem Biol 2011;15(4):475-81
28. Rechfeld F, Gruber P, Hofmann J, et al. Modulators of protein-protein interactions: novel approaches in targeting protein kinases and other pharmaceutically relevant biomolecules. Curr Top Med Chem 2011;11(11):1305-19
29. Buratti E, Brindisi A, Giombi M, et al. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J Biol Chem 2005;280(45):37572-84
30. D'Ambrogio A, Buratti E, Stuani C, et al. Functional mapping of the interaction between TDP-43 and hnRNP A2 in vivo. Nucleic Acids Res 2009;37(12):4116-26
31. Mompean M, Buratti E, Guarnaccia C, et al. Structural characterization of the minimal segment of TDP-43 competent for aggregation. Arch Biochem Biophys 2014;545C(53):62
32. Budini M, Buratti E, Stuani C, et al. Cellular model of TAR DNA-binding protein 43 (TDP-43) aggregation based on its C-terminal Gln/Asn-rich region. J Biol Chem 2012;287(10):7512-25
33. Buratti E, De Conti L, Stuani C, et al. Nuclear factor TDP-43 can affect selected miRNA levels. FEBS J 2010;277(10):2268-81
34. Kawahara Y, Mieda-Sato A. TDP-43 promotes microRNA biogenesis as a component of the drosha and dicer complexes. Proc Natl Acad Sci USA 2012;109(9):3347-52
35. Zhang Z, Almeida S, Lu Y, et al. Downregulation of microRNA-9 in iPSC-derived neurons of FTD/ALS patients with TDP-43 mutations. PLoS One 2013;8(10):e76055
36. Park YY, Kim SB, Han HD, et al. Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology 2013;58(1):182-91
37. Di Carlo V, Grossi E, Laneve P, et al. TDP-43 regulates the microprocessor complex activity during in vitro neuronal differentiation. Mol Neurobiol 2013;48(3):952-63
38. Freischmidt A, Muller K, Ludolph AC, et al. Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis. Acta Neuropathol Commun 2013;1(1):42
39. Colombrita C, Zennaro E, Fallini C, et al. TDP-43 is recruited to stress granules in conditions of oxidative insult. J Neurochem 2009;111(4):1051-61
40. Li YR, King OD, Shorter J, et al. Stress granules as crucibles of ALS pathogenesis. J Cell Biol 2013;201(3):361-72
41. Bentmann E, Haass C, Dormann D. Stress granules in neurodegeneration- lessons learnt from TAR DNA binding protein of 43 kDa and fused in sarcoma. FEBS J 2013;280(18):4348-70
42. Vanderweyde T, Youmans K, Liu-Yesucevitz L, et al. Role of stress granules and RNA-binding proteins in neurodegeneration: a mini-review. Gerontology 2013;59(6):524-33
43. Kim HJ, Raphael AR, Ladow ES, et al. Therapeutic modulation of eIF2alpha phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat Genet 2013. [Epub ahead of print]
44. Johnson BS, Snead D, Lee JJ, et al. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem 2009;284(30):20329-39
45. Lukavsky PJ, Daujotyte D, Tollervey JR, et al. Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. Nat Struct Mol Biol 2013;20(12):1443-9
46. Bhardwaj A, Myers MP, Buratti E, et al. Characterizing TDP-43 interaction with its RNA targets. Nucleic Acids Res 2013;41(9):5062-74
47. Ayala YM, De Conti L, Avendano-Vazquez SE, et al. TDP-43 regulates its mRNA levels through a negative feedback loop. Embo J 2011;30(2):277-88
48. Avendano-Vazquez SE, Dhir A, Bembich S, et al. Autoregulation of TDP-43 mRNA levels involves interplay between transcription, splicing, and alternative polyA site selection. Genes Dev 2012;26(15):1679-84
49. Bembich S, Herzog JS, De Conti L, et al. Predominance of spliceosomal complex formation over polyadenylation site selection in TDP-43 autoregulation. Nucleic Acids Res 2013. [Epub ahead of print]
50. Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 2012;11(2):125-40
51. Baralle D, Lucassen A, Buratti E. Missed threads. The impact of pre-mRNA splicing defects on clinical practice. EMBO Rep 2009;10(8):810-16
52. Ramaswami M, Taylor JP, Parker R. Altered ribostasis: RNA-protein granules in degenerative disorders. Cell 2013;154(4):727-36
53. Vendruscolo M. Proteome folding and aggregation. Curr Opin Struct Biol 2012;22(2):138-43
54. Neumann M. Molecular neuropathology of TDP-43 proteinopathies. Int J Mol Sci 2009;10(1):232-46
55. Buratti E, Baralle FE. The molecular links between TDP-43 dysfunction and neurodegeneration. Adv Genet 2009;66:1-34
56. Lee EB, Lee VM, Trojanowski JQ. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci 2012;13(1):38-50
57. Leitman J, Ulrich Hartl F, Lederkremer GZ. Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress. Nat Commun 2013;4:2753
58. McGoldrick P, Joyce PI, Fisher EM, et al. Rodent models of amyotrophic lateral sclerosis. Biochim Biophys Acta 2013;1832(9):1421-36
59. Yamashita M, Nonaka T, Arai T, et al. Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett 2009;583(14):2419-24
60. Vaccaro A, Patten SA, Ciura S, et al. Methylene blue protects against TDP-43 and FUS neuronal toxicity in C. elegans and D. rerio. PLoS One 2012;7(7):e42117
61. Audet JN, Soucy G, Julien JP. Methylene blue administration fails to confer neuroprotection in two amyotrophic lateral sclerosis mouse models. Neuroscience 2012;209:136-43
62. Vaccaro A, Patten SA, Aggad D, et al. Pharmacological reduction of ER stress protects against TDP-43 neuronal toxicity in vivo. Neurobiol Dis 2013;55:64-75
63. Caccamo A, Majumder S, Deng JJ, et al. Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. J Biol Chem 2009;284(40):27416-24
64. Wang IF, Guo BS, Liu YC, et al. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc Natl Acad Sci USA 2012;109(37):15024-9
65. Lee BH, Lee MJ, Park S, et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 2010;467(7312):179-84
66. Scotter EL, Vance C, Nishimura AL, et al. Differential roles of the ubiquitin proteasome system (UPS) and autophagy in the clearance of soluble and aggregated TDP-43 species. J Cell Sci 2014. [Epub ahead of print]
67. Burkhardt MF, Martinez FJ, Wright S, et al. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol Cell Neurosci 2013;56C(355):64
68. Zheng Y, Zhang WJ, Wang XM. Triptolide with potential medicinal value for diseases of the central nervous system. CNS Neurosci Ther 2013;19(2):76-82
69. Moujalled D, James JL, Parker SJ, et al. Kinase inhibitor screening identifies cyclin-dependent kinases and glycogen synthase kinase 3 as potential modulators of TDP-43 cytosolic accumulation during cell stress. PLoS One 2013;8(6):e67433
70. Wang X, Fan H, Ying Z, et al. Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system. Neurosci Lett 2010;469(1):112-16
71. Gomes C, Escrevente C, Costa J. Mutant superoxide dismutase 1 overexpression in NSC-34 cells: effect of trehalose on aggregation, TDP-43 localization and levels of co-expressed glycoproteins. Neurosci Lett 2010;475(3):145-9
72. Castillo K, Nassif M, Valenzuela V, et al. Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. Autophagy 2013;9(9):1308-20
73. Fang HY, Chen SB, Guo DJ, et al. Proteomic identification of differentially expressed proteins in curcumin-treated MCF-7 cells. Phytomedicine 2011;18(8-9):697-703
74. Duan W, Guo Y, Xiao J, et al. Neuroprotection by monocarbonyl dimethoxycurcumin C: ameliorating the toxicity of mutant TDP-43 via HO-1. Mol Neurobiol 2014;49(1):368-79
75. Cassel JA, McDonnell ME, Velvadapu V, et al. Characterization of a series of 4-aminoquinolines that stimulate caspase-7 mediated cleavage of TDP-43 and inhibit its function. Biochimie 2012;94(9):1974-81
76. Cassel JA, Reitz AB. Ubiquilin-2 (UBQLN2) binds with high affinity to the C-terminal region of TDP-43 and modulates TDP-43 levels in H4 cells: characterization of inhibition by nucleic acids and 4-aminoquinolines. Biochim Biophys Acta 2013;1834(6):964-71
77. Egawa N, Kitaoka S, Tsukita K, et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med 2012;4(145):145ra04
78. Parker SJ, Meyerowitz J, James JL, et al. Inhibition of TDP-43 accumulation by bis(thiosemicarbazonato)-copper complexes. PLoS One 2012;7(8):e42277
79. Boyd JD, Lee-Armandt JP, Feiler MS, et al. A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity. J Biomol Screen 2014;19(1):44-56
80. van Eersel J, Ke YD, Gladbach A, et al. Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons. PLoS One 2011;6(7):e22850
81. Dasuri K, Ebenezer PJ, Uranga RM, et al. Amino acid analog toxicity in primary rat neuronal and astrocyte cultures: implications for protein misfolding and TDP-43 regulation. J Neurosci Res 2011;89(9):1471-7
82. Cristobo I, Larriba MJ, Rios VD, et al. Proteomic analysis of 1alpha, 25-Dihydroxyvitamin D(3) action on human colon cancer cells reveals a link to splicing regulation. J Proteomics 2011;75(2):384-97
83. Dormann D, Capell A, Carlson AM, et al. Proteolytic processing of TAR DNA binding protein-43 by caspases produces C-terminal fragments with disease defining properties independent of progranulin. J Neurochem 2009;110(3):1082-94
84. Leggett C, McGehee DS, Mastrianni J, et al. Tunicamycin produces TDP-43 cytoplasmic inclusions in cultured brain organotypic slices. J Neurol Sci 2012;317(1-2):66-73
85. Volkening K, Leystra-Lantz C, Yang W, et al. Tar DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS). Brain Res 2009;1305:168-82
86. Elden AC, Kim HJ, Hart MP, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010;466(7310):1069-75
87. Nihei Y, Ito D, Suzuki N. Roles of ataxin-2 in pathological cascades mediated by TAR DNA-binding protein 43 (TDP-43) and fused in sarcoma (FUS). J Biol Chem 2012;287(49):41310-23
88. Berkovits BD, Wang L, Guarnieri P, et al. The testis-specific double bromodomain-containing protein BRDT forms a complex with multiple spliceosome components and is required for mRNA splicing and 3'-UTR truncation in round spermatids. Nucleic Acids Res 2012;40(15):7162-75
89. Yu Z, Fan D, Gui B, et al. Neurodegeneration-associated TDP-43 interacts with fragile X mental retardation protein (FMRP)/Staufen (STAU1) and regulates SIRT1 expression in neuronal cells. J Biol Chem 2012;287(27):22560-72
90. Fallini C, Bassell GJ, Rossoll W. The ALS disease protein TDP-43 is actively transported in motor neuron axons and regulates axon outgrowth. Hum Mol Genet 2012;21(16):3703-18
91. Yamazaki T, Chen S, Yu Y, et al. FUS-SMN protein interactions link the motor neuron diseases ALS and SMA. Cell Rep 2012;2(4):799-806
92. Kim SH, Shanware NP, Bowler MJ, et al. Amyotrophic lateral sclerosis-associated proteins TDP-43 and FUS/TLS function in a common biochemical complex to co-regulate HDAC6 mRNA. J Biol Chem 2010;285(44):34097- 105
93. Budini M, Romano V, Avendano-Vazquez SE, et al. Role of selected mutations in the Q/N rich region of TDP-43 in EGFP-12xQ/N-induced aggregate formation. Brain Res 2012;1462:139-50
94. Zhang YJ, Xu YF, Cook C, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci USA 2009;106(18):7607-12
95. Udan-Johns M, Bengoechea R, Bell S, et al. Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones. Hum Mol Genet 2014;23(1):157-70
96. Wang IF, Reddy NM, Shen CK. Higher order arrangement of the eukaryotic nuclear bodies. Proc Natl Acad Sci USA 2002;99(21):13583-8
97. Scofield M, Korutla L, Jackson TG, et al. NAC1, a POZ/BTB protein binds to TDP-43 and has a potential role in amyotrophic lateral sclerosis. Neuroscience 2012;44-54
98. Tanji K, Zhang HX, Mori F, et al. p62/sequestosome 1 binds to TDP-43 in brains with frontotemporal lobar degeneration with TDP-43 inclusions. J Neurosci Res 2012;90(10):2034-42
99. Rubino E, Rainero I, Chio A, et al. SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology 2012;79(15):1556-62
100. Swarup V, Phaneuf D, Dupre N, et al. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB-mediated pathogenic pathways. J Exp Med 2011;208(12):2429-47
101. Hebron ML, Lonskaya I, Sharpe K, et al. Parkin ubiquitinates Tar-DNA binding protein-43 (TDP-43) and promotes its cytosolic accumulation via interaction with histone deacetylase 6 (HDAC6). J Biol Chem 2013;288(6):4103-15
102. Zheng M, Liao M, Cui T, et al. Regulation of nuclear TDP-43 by NR2A-containing NMDA receptors and PTEN. J Cell Sci 2012;125(Pt 6):1556-67
103. Dammer EB, Fallini C, Gozal YM, et al. Coaggregation of RNA-binding proteins in a model of TDP-43 proteinopathy with selective RGG motif methylation and a role for RRM1 ubiquitination. PLoS One 2012;7(6):e38658
104. Keller BA, Volkening K, Droppelmann CA, et al. Co-aggregation of RNA binding proteins in ALS spinal motor neurons: evidence of a common pathogenic mechanism. Acta Neuropathol 2012;124(5):733-47
105. Higashi S, Tsuchiya Y, Araki T, et al. TDP-43 physically interacts with amyotrophic lateral sclerosis-linked mutant CuZn superoxide dismutase. Neurochem Int 2010;57(8):906-13
106. Pokrishevsky E, Grad LI, Yousefi M, et al. Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. PLoS One 2012;7(4):e35050
107. Shan X, Vocadlo D, Krieger C. Mislocalization of TDP-43 in the G93A mutant SOD1 transgenic mouse model of ALS. Neurosci Lett 2009;458(2):70-4
108. Okamoto Y, Ihara M, Urushitani M, et al. An autopsy case of SOD1-related ALS with TDP-43 positive inclusions. Neurology 2011;77(22):1993-5
109. Liu-Yesucevitz L, Bilgutay A, Zhang YJ, et al. Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS One 2010;5(10):e13250
110. Shiina Y, Arima K, Tabunoki H, et al. TDP-43 dimerizes in human cells in culture. Cell Mol Neurobiol 2010;30(4):641-52
111. Kuo PH, Doudeva LG, Wang YT, et al. Structural insights into TDP-43 in nucleic-acid binding and domain interactions. Nucleic Acids Res 2009;37(6):1799-808
112. Cohen TJ, Hwang AW, Unger T, et al. Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking. Embo J 2012;31(5):1241-52
113. Chang CK, Wu TH, Wu CY, et al. The N-terminus of TDP-43 promotes its oligomerization and enhances DNA binding affinity. Biochem Biophys Res Commun 2012;425(2):219-24
114. Zhang T, Mullane PC, Periz G, et al. TDP-43 neurotoxicity and protein aggregation modulated by heat shock factor and insulin/IGF-1 signaling. Hum Mol Genet 2011;20(10):1952-65
115. Wang IF, Chang HY, Hou SC, et al. The self-interaction of native TDP-43 C terminus inhibits its degradation and contributes to early proteinopathies. Nat Commun 2012;3:766
116. Wang YT, Kuo PH, Chiang CH, et al. The truncated C-terminal RNA recognition motif of TDP-43 protein plays a key role in forming proteinaceous aggregates. J Biol Chem 2013;288(13):9049-57
117. Zhang YJ, Caulfield T, Xu YF, et al. The dual functions of the extreme N-terminus of TDP-43 in regulating its biological activity and inclusion formation. Hum Mol Genet 2013;22(15):3112-22
118. Yamashita S, Kimura E, Tawara N, et al. Optineurin is potentially associated with TDP-43 and involved in the pathogenesis of inclusion body myositis. Neuropathol Appl Neurobiol 2013;39(4):406-16
119. Collins M, Riascos D, Kovalik T, et al. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients. Acta Neuropathol 2012;124(5):717-32
120. Bentmann E, Neumann M, Tahirovic S, et al. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43). J Biol Chem 2012;287(27):23079-94
121. Dewey CM, Cenik B, Sephton CF, et al. TDP-43 is directed to stress granules by sorbitol, a novel physiological osmotic and oxidative stressor. Mol Cell Biol 2011;31(5):1098-108
122. Tsuiji H, Iguchi Y, Furuya A, et al. Spliceosome integrity is defective in the motor neuron diseases ALS and SMA. EMBO Mol Med 2013;5(2):221-34
123. Ishihara T, Ariizumi Y, Shiga A, et al. Decreased number of gemini of coiled bodies and U12 snRNA level in amyotrophic lateral sclerosis. Hum Mol Genet 2013;22(20):4136-47
124. Mori F, Kakita A, Takahashi H, et al. Co-localization of bunina bodies and TDP-43 inclusions in lower motor neurons in amyotrophic lateral sclerosis. Neuropathology 2014;34(1):71-6